Status:
COMPLETED
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborating Sponsors:
University of Chicago
Columbia University
Conditions:
Mesothelioma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab
Detailed Description
Secondary endpoints will include: objective response rate overall survival In addition, the objective of the analysis of the correlative science data is to determine any association between tumor e...
Eligibility Criteria
Inclusion
- Inclusion criteria
- 2.1 Patients must have histologically proven malignant mesothelioma (epithelial, sarcomatoid, or mixed subtype) not amenable to curative surgery or radiotherapy. Eligible sites of origin include the pleura, peritoneum, and tunica vaginalis.
- 2.2 Patient's disease must not be amenable to curative treatment with surgery. Evidence of gross unresectability will include but not be limited to direct extension into the chest wall, mediastinal or hilar lymphadenopathy, pulmonary or cardiac function that is inadequate to tolerate resection, and sarcomatoid or mixed histology.
- 2.3 Patients must be \> 18 years old 5.2.4 Patients must have measurable disease.
- Adequate organ function and functional status
- Exclusion Criteria:
- a. General Medical Concerns 5.3.1 Patients must not be pregnant or breast feeding. 5.3.2 No "currently active" second malignancy other than non-melanoma skin cancer. Patients are not considered to have a "currently active" second malignancy if they have completed therapy and have a less than 30% risk of relapse.
- 3.3 No uncontrolled intercurrent illness including but not limited to: active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric/social situations that would limit compliance with study requirements.
- 3.4 No HIV positive patients receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with study medications.
- 3.5 History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab or other agents used in the study.
- 3.6 Inability to interrupt aspirin or other non-steroidal medication for a 5 day period.
- c. Bevacizumab-Specific Concerns
- Subjects meeting any of the following criteria are ineligible for study entry:
- 3.7 Patients with brain metastases are excluded 5.3.8 History of myocardial infarction or CVA (stroke) within 6 months of study entry.
- 3.9 Evidence of bleeding diathesis or coagulopathy. Patients on therapeutic doses of coumadin are eligible as long as the INR is maintained in the range of 2-3 and there is no evidence of active bleeding.
- 3.10 Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study 5.3.11 Urine protein:creatinine ratio less than 1.0 at screening 5.3.12 Serious, non-healing wound, ulcer, or bone fracture
Exclusion
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT00295503
Start Date
February 1 2006
End Date
August 1 2010
Last Update
October 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390-8852